Biotechnology Analyst Zelin discusses chronic graft vs host disease and the opportunity for Syndax Pharmaceuticals (SNDX) and Incyte (INCY) Axatilimab on an Analyst/Industry conference call to be held on June 28 at 2 pm. Webcast Link
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on SNDX:
- BTIG biotechnology analyst to hold an analyst/industry conference call
- 3 Best Stocks to Buy Now, 6/26/2023, According to Top Analysts
- BTIG keeps Buy on Syndax, raises price target to $35
- Cantor Fitzgerald biotech/biopharma to hold analyst/industry conference call
- Syndax Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Clinical and Business Update